Participants with severe withdrawal · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist showed no clear difference in participants with severe withdrawal compared with methadone (low certainty).
1 finding from 1 review
1Small number of events. · People undergoing managed opioid withdrawal
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Peak withdrawal score · People undergoing managed opioid withdrawal
1 finding from 1 review
Overall withdrawal severity · People undergoing managed opioid withdrawal
1 finding from 1 review
Duration of treatment · People undergoing managed opioid withdrawal
1 finding from 1 review
Number experiencing hypotensive or other adverse effects · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist may leads to higher number experiencing hypotensive or other adverse effects compared with methadone (low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist showed no clear difference in drop‐out due to adverse effects compared with methadone (low certainty).
1 finding from 1 review
Completion of treatment · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist showed no clear difference in completion of treatment compared with methadone (low certainty).
1 finding from 1 review
Participants with severe withdrawal · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist probably leads to lower participants with severe withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Completion of treatment · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist probably leads to higher completion of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Peak withdrawal score · Adults or adolescents with opioid dependence
It is very uncertain whether buprenorphine changes mean peak withdrawal score, compared with alpha2‐adrenergic agonists (very low certainty).
1 finding from 1 review
Mean overall withdrawal score (participant rated) · Adults or adolescents with opioid dependence
Buprenorphine showed no clear difference in mean overall withdrawal score, with various methods of assessment compared with alpha2‐adrenergic agonists (moderate certainty).
1 finding from 1 review
Mean days in treatment (with varying scheduled duration) · Adults or adolescents with opioid dependence
Buprenorphine probably leads to higher mean days in treatment (with varying scheduled duration) compared with alpha2‐adrenergic agonists (moderate certainty).
1 finding from 1 review
Number experiencing adverse effects · Adults or adolescents with opioid dependence
It is very uncertain whether buprenorphine changes number experiencing adverse effects compared with alpha2‐adrenergic agonists (very low certainty).
1 finding from 1 review
Number with treatment stopped due to adverse effects · Adults or adolescents with opioid dependence
Buprenorphine showed no clear difference in number with treatment stopped due to adverse effects compared with alpha2‐adrenergic agonists (low certainty).
1 finding from 1 review
Number completing withdrawal treatment · Adults or adolescents with opioid dependence
Buprenorphine probably leads to higher number completing withdrawal treatment compared with alpha2‐adrenergic agonists (moderate certainty).
1 finding from 1 review